Pharmacologic Treatments for PCOS Patients. [Review]
Citation: Clinical Obstetrics & Gynecology. 64(1):55-64, 2021 03 01.PMID: 33346594Institution: MedStar Washington Hospital CenterDepartment: Obstetrics and GynecologyForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Infertility, Female | *Polycystic Ovary Syndrome | Adult | Female | Humans | Infertility, Female/dt [Drug Therapy] | Infertility, Female/et [Etiology] | Life Style | Menstruation Disturbances | Polycystic Ovary Syndrome/dt [Drug Therapy]Year: 2021Local holdings: Available online from MWHC library: March 1996 - present, Available in print through MWHC library: 1999 - March 2003ISSN:- 0009-9201
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 33346594 | Available | 33346594 |
Available online from MWHC library: March 1996 - present, Available in print through MWHC library: 1999 - March 2003
Polycystic ovarian syndrome is the most common endocrinopathy in reproductive-aged women and has a vast array of clinical manifestations. Common clinical presentations of the disorder include anovulatory infertility, menstrual disorders, cutaneous symptoms secondary to androgen excess, metabolic abnormalities and mental health issues. If the condition is left unaddressed or inadequately treated, long-term sequelae such as endometrial hyperplasia, diabetes mellitus and dyslipidemia may ensue, therefore it is imperative for clinicians to address each component of the syndrome. When initial lifestyle changes and dietary modifications do not suffice or fail, pharmacologic therapy should be considered, and when deemed appropriate treatment should be initiated. This review describes the pharmacologic options available to combat the various sequelae commonly seen in women with polycystic ovarian syndrome. Copyright (c) 2020 Wolters Kluwer Health, Inc. All rights reserved.
English